Abstract
Disruption of the body circadian rhythms has been described in the pathogenesis of many health conditions including cancer. Aberrant circadian rhythms indeed, result in deregulation of circadian clock genes and proteins, which may alter cell proliferation and promote oncogenesis and cancer, including melanoma. Moreover, circadian rhythms are often involved in outcomes of anticancer therapy as well. At the molecular level, the mammalian circadian clock is controlled by transcriptional and posttranslational feedback loops comprising a set of key elements, so-called ‘clock genes’ involved in regulation of a wide range of circadian rhythms in physiological processes and behavior. So far, experimental evidence suggests alteration in circadian clock genes’ expression in human melanoma such as for example PER1, PER2, CLOCK and CRY1. However, no comprehensive data on the specific clock genes’ genetic alterations in melanoma were published so far. The current targeted melanoma therapy is mainly directed towards well-established general targets such as for example mutated BRAF and its signaling or towards immunological targets, namely cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1). Still, chronobiological intervention and its potential in melanoma treatment remain an unexploited area. In particular, optimization of melanoma therapy regimens according to the circadian rhythms or circadian clock function activation in melanoma by a particular therapy might represent a new therapeutic approach for treatment of malignant melanoma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
- 2.
- 3.
- 4.
Markova-Car et al. (2014).
- 5.
- 6.
- 7.
Albrecht (2012).
- 8.
Bellet and Sassone-Corsi (2010).
- 9.
Zanello et al. (2000).
- 10.
Bjarnason et al. (2001).
- 11.
Sandu et al. (2012).
- 12.
Salavaty (2015).
- 13.
- 14.
- 15.
International Commission on Radiological Protection (ICRP) (1997).
- 16.
Schernhammer et al. (2011).
- 17.
Azzi et al. (2014).
- 18.
Aguilar-Arnal and Sassone-Corsi (2013).
- 19.
Fang et al. (2016).
- 20.
- 21.
Geyfman et al. (2012).
- 22.
Lengyel et al. (2013a).
- 23.
- 24.
Hamilton et al. (2015).
- 25.
Hamilton et al. (2015).
- 26.
Sancar et al. (2015).
- 27.
Kang et al. (2010).
- 28.
Gaddameedhi et al. (2011).
- 29.
Padua et al. (1984).
- 30.
Inamdar et al. (2010).
- 31.
Shakhova et al. (2012).
- 32.
Besaratinia and Pfeifer (2008).
- 33.
Bollag et al. (2012).
- 34.
- 35.
Melanoma Research Foundation. Melanoma Treatment. Accessed 25.02.2017; American Cancer Society. Treatment of Melanoma Skin Cancer by Stage. Accessed 25.02.2017.
- 36.
Hodis et al. (2012).
- 37.
Krauthammer et al. (2012).
- 38.
- 39.
Johnson et al. (2015).
- 40.
- 41.
Lévi and Okyar (2011).
- 42.
Ortiz-Tudela et al. (2013).
- 43.
Innominato et al. (2010).
- 44.
Ortiz-Tudela et al. (2013).
- 45.
- 46.
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery.
- 47.
Kiessling et al. (2017).
- 48.
We acknowledge the project “Research Infrastructure for Campus-based Laboratories at University of Rijeka”, co-financed by European Regional Development Fund (ERDF).
References
Aguilar-Arnal L, Sassone-Corsi P (2013) The circadian epigenome: how metabolism talks to chromatin remodeling. Curr Opin Cell Biol 25(2):170–176
Albrecht U (2012) Timing to perfection: the biology of central and peripheral circadian clocks. Neuron 74(2):246–260
Alexander W (2016) The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge. P T 41(3):185–191
American Cancer Society. Treatment of Melanoma Skin Cancer by Stage. https://www.cancer.org/cancer/melanoma-skin-cancer/treating/by-stage.html. Accessed 25 Feb 2017
Azzi A, Dallmann R, Casserly A et al (2014) Circadian behavior is light-reprogrammed by plastic DNA methylation. Nat Neurosci 17(3):377–382
Bellet MM, Sassone-Corsi P (2010) Mammalian circadian clock and metabolism – the epigenetic link. J Cell Sci 123(Pt 22):3837–3848
Besaratinia A, Pfeifer GP (2008) Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma. Hum Mutat 29(8):983–991
Bjarnason GA, Jordan RC, Wood PA et al (2001) Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol 158(5):1793–1801
Bollag GE, Tsai J, Zhang J et al (2012) Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11(11):873–886
Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516
Dauchy RT, Xiang S, Mao L et al (2014) Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res 74(15):4099–4110
Desotelle JA, Wilking MJ, Ahmad N (2012) The circadian control of skin and cutaneous photodamage. Photochem Photobiol 88(5):1037–1047
Dronca RS, Leontovich AA, Nevala WK et al (2012) Personalized therapy for metastatic melanoma: could timing be everything? Future Oncol 8(11):1401–1406
Fang M, Hutchinson L, Deng A et al (2016) Common BRAF (V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. Proc Natl Acad Sci U S A 113(5):1250–1255
Gaddameedhi S, Selby CP, Kaufmann WK et al (2011) Control of skin cancer by the circadian rhythm. Proc Natl Acad Sci U S A 108(64):18790–18795
Gery S, Komatsu N, Kawamata N et al (2007) Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res 13(5):1399–1404
Geyfman M, Kumar V, Liu Q et al (2012) Brain and muscle Arnt-like protein-1 (BMAL1) controls circadian cell proliferation and susceptibility to UVB-induced DNA damage in the epidermis. Proc Natl Acad Sci U S A 109(29):11758–11763
Gutierrez D, Arbesman J (2016) Circadian dysrhythmias, physiological aberrations, and the link to skin cancer. Int J Mol Sci 17(5):621
Hamilton N, Diaz-de-Cerio N, Whitmore D (2015) Impaired light detection of the circadian clock in a zebrafish melanoma model. Cell Cycle 14(8):1232–1241
Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723
Hodis E, Watson IR, Kryukov GV et al (2012) A landscape of driver mutations in melanoma. Cell 150(2):251–263
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery. https://clinicaltrials.gov/ct2/show/NCT01328535?term=melanoma+and+temozolomide+and+mayo&rank=1
Inamdar GS, Madhunapantula SV, Robertson GP (2010) Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol 80(5):624–637
Innominato PF, Lévi FA, Bjarnason GA (2010) Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev 62(9–10):979–1001
International Commission on Radiological Protection (ICRP) (1997) General principles for the radiation protection of workers. Ann ICRP 27(1):1–60
Johnson DB, Peng C, Sosman JA (2015) Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol 7(2):97–106
Kang T-H, Lindsey-Boltz LA, Reardon JT et al (2010) Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase. Proc Natl Acad Sci U S A 107(11):4890–4895
Kiessling S, Beaulieu-Laroche L, Blum ID et al (2017) Enhancing circadian clock function in cancer cells inhibits tumor growth. BMC Biol 15(1):13
Kleszczyński K, Hardkop LH, Fischer TW (2011) Differential effects of melatonin as a broad range UV-damage preventive dermato-endocrine regulator. Dermatoendocrinol 3(1):27–31
Kosary CL, Altekruse SF, Ruhl J et al (2014) Clinical and prognostic factors for melanoma of the skin using SEER registries: collaborative stage data collection system, version 1 and version 2. Cancer 120(Suppl 23):3807–3814
Krauthammer M, Kong Y, Ha BH et al (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44(9):1006–1014
Kvaskoff M, Weinstein P (2010) Are some melanomas caused by artificial light? Med Hypotheses 75(3):305–311
Lee JT, Li L, Brafford PA et al (2010) PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 23(6):820–827
Lengyel Z, Lovig C, Kommedal S et al (2013a) Altered expression patterns of clock gene mRNAs and clock proteins in human skin tumors. Tumor Biol 34(2):811–819
Lengyel Z, Battyáni Z, Szekeres G et al (2013b) Circadian clocks and tumor biology: what is to learn from human skin biopsies? Gen Comp Endocrinol 188:67–74
Leontovich AA, Dronca RS, Suman VJ et al (2012) Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed) 4:958–975
Lévi F, Okyar A (2011) Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Expert Opin Drug Deliv 8(12):1535–1541
Li S, Ao X, Wu H (2013) The role of circadian rhythm in breast cancer. Chin J Cancer Res 25(4):442–450
Markova-Car EP, Jurišić D, Ilić N et al (2014) Running for time: circadian rhythms and melanoma. Tumour Biol 35(9):8359–8368
Melanoma Research Foundation. Melanoma Treatment. https://www.melanoma.org/understand-melanoma/melanoma-treatment. Accessed 25 Feb 2017
Ortiz-Tudela E, Mteyrek A, Ballesta A et al (2013) Cancer chronotherapeutics: experimental, theoretical, and clinical aspects. Handb Exp Pharmacol 2017:261–288
Padua RA, Barrass N, Currie GA (1984) A novel transforming gene in a human malignant melanoma cell line. Nature 311(5987):671–673
Plikus MV, Van Spyk EN, Pham K et al (2015) The circadian clock in skin: implications for adult stem cells, tissue regeneration, cancer, aging, and immunity. J Biol Rhythms 30(3):163–182
Pukkala E, Helminen M, Haldorsen T et al (2012) Cancer incidence among Nordic airline cabin crew. Int J Cancer 131(12):2886–2897
Pukkala E, Martinsen JI, Weiderpass E et al (2014) Cancer incidence among firefighters: 45 years of follow-up in five Nordic countries. Occup Environ Med 71(6):398–404
Ravnan MC, Matalka MS (2012) Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther 34(7):1474–1486
Robert C, Schachter J, Long GV et al (2015a) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532
Robert C, Long GV, Brady B et al (2015b) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330
Sahar S, Sassone-Corsi P (2009) Metabolism and cancer: the circadian clock connection. Nat Rev Cancer 9(12):886–896
Salavaty A (2015) Carcinogenic effects of circadian disruption: an epigenetic viewpoint. Chin J Cancer 34(9):375–383
Sancar A, Lindsey-Boltz LA, Gaddameedhi S et al (2015) Circadian clock, cancer, and chemotherapy. Biochemistry 54(2):110–123
Sandu C, Dumas M, Malan A et al (2012) Human skin keratinocytes, melanocytes, and fibroblasts contain distinct circadian clock machineries. Cell Mol Life Sci 69(19):3329–3339
Schernhammer ES, Razavi P, Li TY et al (2011) Rotating night shifts and risk of skin cancer in the nurses’ health study. J Natl Cancer Inst 103(7):602–606
Shakhova O, Zingg D, Schaefer SM et al (2012) Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 14(8):882–890
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30
Slominski A, Fischer TW, Zmijewski MA et al (2005) On the role of melatonin in skin physiology and pathology. Endocrine 27(2):137–148
Taniguchi H, Fernández AF, Setién F et al (2009) Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res 69(21):8447–8454
Tsai J, Lee JT, Wang W et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105(8):3041–3046
Yang MY, Chang JG, Lin PM et al (2006) Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci 97(12):1298–1307
Yi C, Zhang Y, Yu Z et al (2014) Melatonin enhances the anti-tumor effect of fisetin by inhibiting COX-2/iNOS and NF-κB/p300 signaling pathways. PLoS One 9(7):e99943
Yu HS, Reiter RJ (eds) (1993) Melatonin biosynthesis, physiological effects, and clinical applications. CRC Press, Boca Raton
Zanello SB, Jackson DM, Holick MF (2000) Expression of the circadian clock genes clock and period1 in human skin. J Invest Dermatol 115(4):757–760
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Markova-Car, E.P., Jurišić, D., Ružak, N., Kraljević Pavelić, S. (2019). Circadian Rhythms and Personalized Melanoma Therapy. In: Bodiroga-Vukobrat, N., Rukavina, D., Pavelić, K., Sander, G.G. (eds) Personalized Medicine in Healthcare Systems. Europeanization and Globalization, vol 5. Springer, Cham. https://doi.org/10.1007/978-3-030-16465-2_27
Download citation
DOI: https://doi.org/10.1007/978-3-030-16465-2_27
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-16464-5
Online ISBN: 978-3-030-16465-2
eBook Packages: Law and CriminologyLaw and Criminology (R0)